Caucasian male and female participants age 18 years of age and older will be enrolled in this study if they have known birch or peanut allergies or known to be non-atopic. Participants will undergo skin testing to confirm their allergies if not completed in the last 12 months. Medications and medical history will be captured with a focus on atopic disorders. Participants will undergo birch and peanut patch testing to assess penetration and if potential correlation exists with filaggrin genotyping and phenotyping. Blood samples will be drawn from participants and DNA isolated for genotyping of null mutations in filaggrin.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* caucasian male or females
* participants 18 years of age and older
* participants with known birch allergy, confirmed by a skin test 3mm or greater than the negative control
* participants with diagnosed and confirmed peanut with allergy
* confirmed by one of the following:
* positive food challenge
* convincing history of peanut allergy AND positive skin test (3mm \>= than negative control) OR peanut-specific IgE \>=0.35
* uncertain history of peanut allergy OR no exposure to peanut AND a positive skin test 5mm\>= negative control AND a peanut-specific IgE \>=15
* non-allergic controls who lack a diagnosis of any atopic diathesis and have supportive negative skin testing to a panel of common environmental allergens.
Exclusion criteria:
* participants unable to complete study related procedures
* participants that have taken or are taking restricted medications
Primary outcome measure(s)
Peanut patch testing — Up to 17 months Differences in patch test positive responses to peanut allergen (extract plus raw peanut butter preparations) between participants with confirmed peanut allergy, confirmed birch allergy and non-atopic controls.
Responses are graded as:
Negative (-) Irritant reaction (IR) Equivocal / uncertain (+/-) Weak positive (+) Strong positive (++) Very Strong Positive (+++)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
